Arca
Skip to content
Tools
Tools

SYK: Tyrosine-protein kinase SYK

Non-receptor tyrosine kinase which mediates signal transduction downstream of a variety of transmembrane receptors including classical immunoreceptors like the B-cell receptor (BCR).

  • Drugs that act on it: 13
  • Approved: 1
  • In phases 1 to 3: 12
  • Sponsors: 6

Who is on it, and how far along

Every drug ChEMBL records acting on SYK, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 11
  • Other 2

Approved1

  • Fostamatinib

Phase 32

  • Entospletinib
  • Sovleplenib

Phase 29

  • Cerdulatinib
  • Gusacitinib
  • Lanraplenib
  • Mivavotinib
  • R-112
  • R-333
  • R-343
  • R-348
  • R-406

Phase 11

  • PRT-2607

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

  • Asana BioSciences18%
  • Calithera Biosciences, Inc18%
  • Dermavant Sciences GmbH18%
  • Hutchmed18%

The landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Tyrosine-protein kinase SYK inhibitor.
FostamatinibApprovedRigel PharmaceuticalsSmall moleculeInhibitor8
EntospletinibPhase 3Gilead SciencesSmall moleculeInhibitor1
SovleplenibPhase 3HutchmedSmall moleculeInhibitor1
CerdulatinibPhase 2Dermavant Sciences GmbHSmall moleculeInhibitor0
GusacitinibPhase 2Asana BioSciencesSmall moleculeInhibitor0
LanraplenibPhase 2Gilead SciencesSmall moleculeInhibitor0
MivavotinibPhase 2Calithera Biosciences, IncSmall moleculeInhibitor0
R-112Phase 2—Small moleculeInhibitor0
R-333Phase 2Rigel PharmaceuticalsOtherInhibitor0
R-343Phase 2Rigel PharmaceuticalsSmall moleculeInhibitor0
R-348Phase 2Rigel PharmaceuticalsSmall moleculeInhibitor0
R-406Phase 2—Small moleculeInhibitor0
PRT-2607Phase 1—OtherInhibitor0

Open trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 10 in all, from ClinicalTrials.gov.
Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific AntibodiesFostamatinibPhase 1RecruitingNational Heart, Lung, and Blood Institute (NHLBI)Apr 29, 2025
Special Drug Use-results Survey for Long-term Use (Fostamatinib)Fostamatinib—RecruitingKissei Pharmaceutical Co., Ltd.Jan 3, 2025
Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic CancerFostamatinibPhase 1RecruitingUniversity of California, San DiegoOct 15, 2024
Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized AdultsFostamatinibPhase 2Not yet recruitingInova Health Care ServicesAug 21, 2024
Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHDFostamatinibPhase 1RecruitingStefanie Sarantopoulos, MD, PhD.Jan 31, 2024
Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell DiseaseFostamatinibPhase 1RecruitingNational Heart, Lung, and Blood Institute (NHLBI)Jun 15, 2023
HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaSovleplenibPhase 2 / Phase 3Active, not recruitingHutchmedSep 10, 2022
A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaFostamatinibPhase 3Enrolling by invitationRigel PharmaceuticalsOct 25, 2019
Fostamatinib in the Treatment of Chronic Active Antibody Mediated RejectionFostamatinibPhase 1 / Phase 2Active, not recruitingImperial College LondonJun 19, 2019
Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaEntospletinibPhase 2 / Phase 3RecruitingBeat AML, LLCJan 9, 2017

Diseases most associated with it

Open Targets association score, 0 to 1; all associations
  • Immunodeficiency 82 with systemic inflammation0.64
  • Immunodeficiency disease0.57
  • Decreased circulating immunoglobulin concentration0.56
  • Autoimmune thrombocytopenic purpura0.52
  • Exanthem0.48
  • Arthritic joint disease0.47
  • Lung carcinoma0.39
  • Esophageal adenocarcinoma0.38

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2599, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-19. Gene name, function (UniProt P43405, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.